Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Korábbi kezelés

• Patients with severe concurrent infections;
• Patients who have undergone grade II or higher surgery within 3 weeks prior to treatment;
• Patients with known hypersensitivity to components of the investigational drug.

Más betegség

• Patients with coexisting hematologic disorders (e.g., hemophilia, myelofibrosis) deemed unsuitable for inclusion by the investigator;
• Patients with substance abuse, medical, psychological, or social conditions that may interfere with study participation or the evaluation of study outcomes;

Laborértékek

• Patients with impaired liver or kidney function, specifically defined as serum direct bilirubin, indirect bilirubin, and/or ALT, AST, or serum creatinine >2 times the upper limit of normal (ULN), unless such abnormalities are attributed to lymphoma;
• Patients with bone marrow failure, defined as absolute neutrophil count (ANC) <1.5×10⁹/L or platelets <75×10⁹/L;
• Patients with chronic heart failure classified as NYHA class III or IV, or left ventricular ejection fraction (LVEF) <50%, or those with a history of the following cardiac events within the past 6 months: acute coronary syndrome, acute heart failure (NYHA class III or IV), or significant ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, or resuscitated sudden cardiac arrest);
• Patients with AIDS, syphilis, or active hepatitis B (HBV DNA >1×10⁴ copies/mL) or hepatitis C infection;

Egyéb

• Patients who have experienced grade III or higher neurotoxicity within the past 2 weeks;
• Patients deemed unsuitable for enrollment by the investigator;

• Diagnosed with EBV infectious diseases, including infectious mononucleosis, chronic active EBV infection, or other EBV infectious diseases;
• EBV DNA ≥ 10⁴ copies/mL in whole blood or plasma;
• Age ≤ 75 years with ECOG performance status ≤ 2;
• Estimated life expectancy over 3 months;
• Patients must be able to undergo follow-up. They should understand the nature of their disease and voluntarily agree to participate in this study for treatment and follow-up.